Insilico’s flagship suite includes PandaOmics (multi-omics target identification), Chemistry42 (de novo molecular design), and InClinico (clinical outcome prediction). By leveraging these AI modules, they can rapidly generate novel molecules, predict safe

Yoda Pharmaceuticals Inc.Taiwan Branch (Cayman) leverages its AI-driven drug discovery platform, dedicating itself to addressing multiple unmet medical needs, exploring and developing highly potential and highly effective products to bring brand new hope to patients.
1. Neurological Diseases: YA-101 Multiple System Atrophy (MSA); YA-102 Parkinson's Disease (PD); YA-201 Alzheimer's Disease (AD)
2. Psychiatric Disorders: YA-301 Schizophrenia; YA-401 Autism
3. Cerebrovascular Diseases: YA-501 Ischemic Stroke; YA-502 Traumatic Brain Injury
(The content above was translated by AI.)

Neurology
Pipeline
Utilizing Yoda’s proprietary AI-based drug screening platform, we engage in the exploration and development of promising and beneficial products to address unmet medical needs, instilling new hope in patients.YA-101 Multiple System Atro

iSharing is a digital public welfare network system designed specifically for charitable donations, material distribution, social welfare organizations, and government management—establishing a fully transparent donation history.